Navigation Links
WuXi PharmaTech Schedules First-Quarter 2013 Earnings Release
Date:4/10/2013

SHANGHAI, April 10, 2013 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release financial results for the first quarter of 2013 after the New York Stock Exchange closes on Monday, May 13, 2013 (which will be Tuesday morning, May 14, 2013 Shanghai time). The earnings release will be available on the investor relations section of the Company's website at http://www.wuxiapptec.com/.

Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 8:00 am (U.S. Eastern) / 5:00 am (U.S. Pacific) / 8:00 pm (Beijing/Shanghai/Hong Kong) on Tuesday, May 14, 2013, to discuss the first-quarter 2013 financial results and recent business activities. The conference call may be accessed by calling: United States:

1-866-519-4004 China (Landline):

800-819-0121 China (Mobile):

400-620-8038Hong Kong:

800-930-346United Kingdom:

0-808-234-6646International:

+65-6723-9381 Conference ID: 35582613A telephone replay will be available two hours after the call's completion at:

United States:

1-855-452-5696 China (Landline):

800-870-0205China (Mobile):

400-120-0932Hong Kong:

800-963-117United Kingdom:

0-808-234-0072International:

+61-2-8199-0299 Conference ID:

35582613A live webcast of the conference call and replay will be available in the investor relations section of WuXi PharmaTech's website at http://www.wuxiapptec.com/.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.

For more information, please contact:

Ronald Aldridge
Director of Investor Relations
WuXi PharmaTech (Cayman) Inc.
Tel: +1-201-585-2048
Email: Ron_Aldridge@wuxiapptec.com
Web: http://www.wuxiapptec.com


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Breckenridge announces agreement with Aptalis Pharmatech to market Propranolol Hydrochloride Extended-Release Capsules
2. WuXi PharmaTech Receives Letter from AAALAC Commending Animal Care at Suzhou Toxicology Facility as "Exemplary"
3. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2012 Results, Share Repurchase Program
4. WuXi PharmaTech and Open Monoclonal Technology Expand Human Antibody Development and Commercial Opportunities for Asian Regional and Global Pharmaceutical Companies
5. WuXi PharmaTech Schedules Fourth-Quarter 2012 Earnings Release
6. WuXi PharmaTech Presents the 2012 Life Science and Chemistry Awards
7. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2012 Annual General Meeting
8. WuXi PharmaTech Celebrates Dr. Joseph Vaccas Induction into American Chemical Societys Medicinal Chemistry Hall of Fame
9. WuXi PharmaTech and Open Monoclonal Technology Announce OmniRat(TM) Antibody Collaboration
10. WuXi PharmaTech to Manufacture Ibalizumab for TaiMed Biologics
11. WuXi PharmaTech Receives GLP Certificate from SFDA for Suzhou Toxicology Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... Research and Markets has announced the addition of the "Rosacea Drugs ... ... Price Analysis and Strategies - 2016, provides drug pricing data and benchmarks ... questions: What are the key drugs marketed for ... Rosacea market? What are the unit prices and annual ...
(Date:2/20/2017)... , Feb. 20, 2017 EU5 Magnetic Resonance Imaging ... ... "EU5 Magnetic Resonance Imaging (MRI) Systems Market Outlook to 2022", provides ... market. The report provides value, in millions of US dollars, volume ... MRI Systems and 1.5T MRI Systems. The report ...
(Date:2/20/2017)... 20, 2017 Provides understanding and access ... into by the worlds leading healthcare companies. ... Description The Global Anemia Partnering Terms and Agreements ... partnering deals and agreements entered into by the ... in partnering deals - Top deals by ...
Breaking Medicine Technology:
(Date:2/20/2017)... BROOK, Ill. (PRWEB) , ... February 20, 2017 ... ... potential to reduce the rate at which women are called back for additional ... the journal Radiology . , In 2011, the U.S. Food and Drug ...
(Date:2/20/2017)... ... ... Silverado today is pleased to announce that it has entered into a ... in Alexandria, Virginia. The new community is expected to open its doors in the ... The three-story community with underground parking – located on King Street –will serve 66 ...
(Date:2/20/2017)... ... February 20, 2017 , ... Clearwave ... that runs on the Posiflex XT-series of touch screen terminals. Both companies will ... in Orlando, Florida. The terminal provider Posiflex is helping to bridge the gap ...
(Date:2/20/2017)... BOSTON, MA (PRWEB) , ... February 20, 2017 ... ... oncology prowess is now available as an employee health benefit for companies that ... network of expert clinical consultation providers, employees will have access to Watson’s suite ...
(Date:2/20/2017)... Dallas, TX (PRWEB) , ... February 20, 2017 , ... ... launch of Sensory Sensitive Sundays, a joint event at Chuck E. Cheese’s locations throughout ... (ASD) and other special needs, the opportunity to experience the fun of visiting Chuck ...
Breaking Medicine News(10 mins):